Abstract 1383
Background
Ewing’s sarcoma (ES) is a highly malignant primary bone tumor, and ewing’s sarcoma stem cells (CSCs) are the main cause of tumor recurrence and metastasis. This paper will further discuss the mechanism of let-7a in the development and progression of ewing’s sarcoma CSCs, laying an experimental basis and theoretical basis for the biological treatment of ewing’s sarcoma.
Methods
In this study, we intend to isolate CSCs from ES cells cultured in vitro by side group cell sorting and flow cytometry, and then detect the effect of let-7a on the malignant phenotype of ewing’s sarcoma CSCs, and further verify the regulatory role of let-7a in ewing’s sarcoma CSCs in vitro and in vivo experiments.
Results
We successfully isolated Ewing sarcoma cancer stem cells(CSCs) by side population cells (SP) sorting method. The immunohistochemical results showed that STAT3 was highly expressed in ES tissues and negatively correlated with let-7a.Overexpression of the let - 7a can suppress the malignant phenotype of Ewing sarcoma CSCs, and inhibited the growth of subcutaneous xenograft tumor of ewing’s sarcoma CSCs.Bioinformatics analysis found that singal transducer and activator of transcription 3 (STAT3) is a direct target gene of let - 7a, STAT3 and its downstream factor lin28 form a positive feedback loop with let-7a, participate in Ewing sarcoma CSCs function regulation.
Conclusions
let-7a suppress Ewing sarcoma CSCs’ malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The second affiliated Hospital of Nanchang University.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract